EMA issues guidance on medicine impurities, in light of nitrosamine detection
After nitrosamines were detected in sartan medicines, the EMA has released new recommendations about handling and reporting impurities in drugs.
List view / Grid view
News
Inhaled formulation of remdesivir to be tested as COVID-19 treatment
Gilead Sciences has said it will initiate clinical trials in August to test an inhaled formulation of remdesivir, a potential COVID-19 therapy.
Ruxolitinib to be studied as COVID-19 treatment in clinical trial
Following the successful treatment of a COVID-19 patient with ARDS using ruxolitinib, Germany is set to begin clinical trials to test the drug.
GSK recalls three lots of children’s cough medicine in US
GlaxoSmithKline has voluntarily recalled two lots of Children's Robitussin® Honey Cough and Chest Congestion DM and one lot of Children's Dimetapp® Cold and Cough in the US.
Glenmark approved to supply favipiravir as COVID-19 treatment in India
Indian authorities have given their first approval for the oral antiviral favipiravir for treatment of COVID-19 to Glenmark Pharmaceuticals.
Novel prostate cancer drug formulation could improve drug’s efficacy
A new oil-based oral formulation of prostate cancer drug abiraterone acetate could enable a smaller dose of the drug to be effective and reduce possible side effects, a study has shown.
Dexamethasone to be available on NHS as COVID-19 treatment
The UK government has approved dexamethasone to be available on the NHS, following clinical trials proving its efficacy at reducing the risk of death for COVID-19 patients.
UK launches scheme to encourage development of novel antibiotics
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
Clinical trial disruption from COVID-19 beginning to lessen, says report
New findings reveal that the 200 clinical trials impacted and delayed by COVID-19 are now continuing or have completed their course.
AstraZeneca commits to supply Europe with 400 million doses of COVID-19 vaccine candidate
AstraZeneca plans to produce up to 400 million doses of the University of Oxford’s COVID-19 vaccine candidate, with deliveries to begin by the end of the year.
Nine in 10 Americans concerned big pharma will use COVID-19 to raise drug prices
A survey of US adults has revealed that the majority are very or somewhat worried that big pharma will take advantage of the COVID-19 pandemic to increase the price of drugs.
Torbay Pharmaceuticals recalls two batches of Epistatus (midazolam)
Due to a potentially faulty and incorrectly engaged child-resistant container closure, Torbay Pharmaceuticals has announced a recall of certain Epistatus (midazolam) batches.
SFX‐01 to enter Phase II/III trials to test efficacy against COVID-19 symptoms
The drug candidate SFX-01 is set to be studied in Phase II/III trials to test its efficacy at treating acute respiratory distress syndrome (ARDS), a complication of COVID‐19.
Generic remdesivir may put pricing pressure on Indian pharma, says analyst
According to an expert, Indian pharmaceutical companies will have to price remdesivir cautiously to ward off generic competition in the near future.
MHRA suspends patient recruitment to UK COVID-19 hydroxychloroquine trials
After evidence suggesting hydroxychloroquine has no benefit against COVID-19, the MHRA has suspended further recruitment to clinical trials investigating the drug in the UK.
